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Abstract 
BACKGROUND: Paclitaxel-induced peripheral neuropathy is the most important side effect limiting the use of this 
medication.  
AIM: This study aimed to compare the effects of omega-3 and vitamin E on the incidence of peripheral 
neuropathy in patients receiving Taxol.  
METHODS: In this clinical trial, 63 patients who were a candidate for receiving taxol, were enrolled based on 
inclusion and exclusion criteria. In group O, patients received 640 mg omega-3 three times a day, and group E, 
received 300 mg vitamin E two times a day. Patients took the supplements up to three months after the onset of 
Taxol. Group P received placebo for a similar period. All patients referred to a neurologist for electrophysiological 
evaluation before the onset of chemotherapy and at months 1 and 3. The presence of neuropathy and its 
progression was recorded by the neurologist.  
RESULTS: Neurological examination in this study indicated that 6 patients (28.6%) in Group O, 7 patients 
(33.3%) in group E, and 15 patients (71.4%) in placebo group started peripheral neuropathy. There was a 
significant difference between intervention groups and the placebo group (p = 0.0001) and no significant 
difference between intervention groups (p = 0.751). 
CONCLUSION: Our data suggested that vitamin E and omega-3 may significantly reduce the incidence of 
Paclitaxel-induced peripheral neuropathy. Routine administration of such supplements that have no special side 
effect for patients under chemotherapy may greatly enhance their quality of life. 
 
 
 
 
 
 
 
Introduction 
 
Taxol is one of the taxane-derived 
chemotherapeutic agents used to treat solid tumours 
such as breast, ovary, lung and Kaposi's sarcoma. 
The source of this drug is a plant called Taxus 
brevifolia, a native of North America. Taxol is anti 
microtubular agent that causes polymerisation of the 
tubulin, and it also leads to the formation of stable 
microtubules without dynamic instability [1] [2]. 
Peripheral neuropathy is likely to be the major side 
effect of Taxol. The exact pathology of this 
complication is still not well known. Due to the 
accumulation of microtubules in axons and Schwann 
cells, Taxol causes an axonal sensory peripheral 
neuropathy. This drug, even in more severe cases, 
may also cause fibre demyelination [1]. It usually 
takes three weeks to develop toxic, toxic signs of 
Taxol, which affects the sensory nervous system more 
than the autonomic nervous system (ANS). The most 
common symptoms of taxol due to neuropathy include 
anaesthesia, paresthesia and burning pain in the 
gloves. The onset of symptoms often occurs in the 
hands and feet simultaneously, and some patients 
also complain of discomfort [3] [4]. 
Omega-3 fatty acids, such as EPA and DHA, 
are unsaturated fatty acids present in phospholipid 
membranes of cells, including central and peripheral 
nervous system cells [5]. They have very beneficial 
effects in some psychiatric and neurodegenerative 
diseases. They play a decisive role in the biophysical 
properties of neuronal membranes and modulate the 
signal transduction by effects on ion channels and 
receptor function [6]. In addition, the production of 
Clinical Science  
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1858                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
anti-inflammatory cytokines that cause neuropathy is 
reduced by these fatty acids, especially DHA [5] [6]. 
DHA-linked myelogenesis has been proven in recent 
studies [7]. Vitamin E is widely used to prevent 
diseases caused by oxidative stress. Its vital effects 
on neuronal function have been indicated in many 
diseases of vitamin E deficiency and central and 
peripheral nervous system manifestations. Studies 
have shown that neuropathic effects of cisplatin may 
have neuroprotective effects [8] [9]. Another study 
found that vitamin E was effectively and safely 
protected against neuropathy in cancer patients 
treated with taxol [10]. Most side effects of 
chemotherapy are eliminated after treatment 
discontinuation, but peripheral neuropathy may be 
somewhat reversible or irreversible in some patients, 
which can have adverse effects on the patient's 
quality of life. Therefore, this study aimed to compare 
the effect of omega-3 and vitamin E on the incidence 
of peripheral neuropathy in taxol recipients. 
 
 
Material and Methods 
 
All procedures performed in studies involving 
human participants were in accordance with the 
ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki 
Declaration and its later amendments or comparable 
ethical standards, and was approved by Arak 
University of Medical Sciences Institutional Review 
Board (Protocol number IR.ARAKMU.REC.2015.219; 
November 23, 2015). 
In this clinical trial study, 63 patients aged 30-
70 years who received taxol from Ayatollah Khansari 
Hospital in Arak city were included in the study. 
Inclusion criteria included all patients with a solid 
tumour (lung, breast, ovaries, etc.), patients with a 
good liver and kidney status that received the first 
taxol treatment. 
Exclusion criteria include patients with 
previous history of chemotherapy, the presence of 
neuropathy due to diabetes, AIDS, alcohol abuse, 
thyroid dysfunction and hereditary neuropathy, the 
use of any dietary supplement (fish oil, vitamins and 
minerals) at least three months before entering the 
study, smoking and drugs use, low back pain and the 
use of other chemotherapy drugs. 
Blood samples were taken from patients for 
liver and kidney function, and BUN, creatinine, ALT 
and AST values were measured. Patient's history of 
treatment was also fully completed. Then, the patients 
were randomly divided into three equal groups 
according to the number table. In the first group 
(group O), patients received omega-3 capsules of 640 
mg three times a day while receiving taxol (11), the 
second group (group E) received vitamin E 
supplements at a dose 300 mg twice daily (10). The 
duration of use of omega-3 and vitamin E was 
determined from the time of receipt of taxol to three 
months after its discontinuation. In the third group 
(group P), patients also used placebo capsules for the 
same period. 
Before chemotherapy and one and three 
months later, all patients were examined by a 
neurologist who is responsible for the clinical and 
electrophysiological evaluation of the patients. Then 
the presence of neuropathy was recorded by the 
specialist. The person who registered the information 
was not aware of the patient's group, and the patients 
were not aware of their position in the relevant groups 
considering the medical ethics conditions. 
After completing the checklist, data were 
entered into the SPSS software version 20. The 
analytical analysis was performed with appropriate 
methods such as independent T-test or nonparametric 
methods to test the difference in mean in different 
groups. Paired t-test was used to compare the 
quantitative parameters at the beginning of the study 
and after 4 months of treatment, while the qualitative 
data were analysed using the chi-square test. 
 
 
Results 
 
In this study, 69 patients with different types 
of cancers were studied. Six patients were excluded 
from the study due to discontinuation of the drug. 
Finally, 63 patients were evaluated in three groups. In 
the omega-3 group, 15 women (71.4%) and 6 men 
(28.6%) were present. In the vitamin E group, 16 
women (76.2%) and 5 men (23.8%) were admitted, 
while 15 (71.4%) and 6 men (28.6%) were presented 
in the control group. Data analysis using chi-square 
test depicted that there was no significant difference 
between the three groups regarding gender (p = 
0.886), (Figure 1). 
 
Figure 1: Frequency of sex in three groups 
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The mean age of patients in the group O was 
51.5 ± 9.2 years, followed by 50.9 ± 10.4 years in the 
group E and 52.2 ± 10.1 years in the group P. The t-
test revealed no significant difference between the 
age of three groups (p = 0.664), (Figure 2). 
 
Figure 2: The mean age (± standard deviation) of patients in three 
groups of malignancy 
 
The mean age (± standard deviation) of 
patients was shown in figure 2. Accordingly, 17 
patients (27.0%) suffered from various types of lung 
cancer, followed by patients with breast cancer 
(57.1%, 36 individuals) and ovarian cancer (15.9%, 10 
patients). 
In the omega-3 group, 11 patients (52.4%) 
had breast cancer, followed by lung cancer (28.6%, 6 
cases) and ovarian cancer (19%, 4 cases). 
In the vitamin E group, 12 (57.1%) had breast 
cancer, followed by lung cancer (23.8%, 5 cases) and 
ovarian cancer (19%, 4 cases). In the placebo group, 
13 (61.9%) had breast cancer, followed by lung 
cancer (28.6%, 6 cases) and ovarian cancer (9.5%, 2 
cases), (Figure 3, and Table 1). Chi-square test 
exhibited no significant difference in the type of 
malignancy between the groups (p = 0.448). 
 
Figure 3: Malignancy in three groups 
Table 1: Demographic and baseline variables in three groups 
 Omega-3 Vitamin E Placebo P-value 
Gender (female) (4.17 )%71 (2.17 )%77 (4.17 )%71 0.861 
Age (year) 2.9±1.17 4.71±9.11 7.71±2.12 0.664 
Body mass index (kg / m2) 1.1±3.24 2.7±8.24 4.7±2.21 0.780 
The type of malignancy 
Lung cancer 
 
(7.28 )%7 
 
(8.23 )%1 
 
(7.28 )%7 
 
Breast cancer (4.12 )%77 (7.11 )%72 (9.77 )%73 0.482 
Ovarian cancer (1.79 )4 (1.79 )4 (1.9 )%2  
 
There was no significant difference between 
the groups receiving the drug and the placebo group 
(p = 0.0001). However, the difference between the two 
groups of omega 3 and vitamin E was not significant 
(p = 0.751). Figure 4 shows the incidence and severity 
of peripheral neuropathy among the patients. 
 
Figure 4: The incidence and severity of peripheral neuropathy in the 
three groups 
 
In the present study, the peripheral nerves 
were examined electrophysiologically. To evaluate 
motor neurons, two ulnar and peroneal nerves were 
evaluated, and the sural and ulnar nerves were 
assessed for sensory function.  
Table 2: Overall incidence and severity of peripheral 
neuropathy in patients in three groups 
 Without 
neuropathy 
Mild neuropathy Medium 
Neuropathy 
Severe 
neuropathy 
Omega-3 (4.17 )%71 (79 )%4 (8.4 )%7 (8.4 )%7 
Vitamin E (1.77 )%74 (3.74 )%3 (3.74 )%3 (8.4 )%7 
Placebo (7.28 )%7 (3.33 )1 (79 )%4 (79 )%4 
 
In these studies, motor delay (DL), amplitude 
(Amp), conduction velocity (CV) was measured. 
Electrophysiological variables of motor neurons and 
sensory nerves were indicated in Table 3 and 4. 
Table 3: Electrophysiological variables of motor neurons 
during study period 
 Group Before 
chemotherapy 
One month 
later 
Three 
months 
later 
P-value 
Ulnar nerve 
DL (ms) 
 
 
CV (m/s) 
 
 
Amp (mV) 
 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
 
 
84.2 
87.2 
11.2 
72.49 
74.49 
19.49 
77.7 
11.7 
74.7 
 
94.2 
98.2 
74.3 
34.49 
31.49 
42.49 
17.1 
91.7 
17.1 
 
71.3 
77.3 
27.3 
27.11 
28.11 
77.11 
11.1 
49.1 
81.1 
 
 
0.720 
 
 
0.431 
 
 
0.446 
 
 
Peroneal nerve 
DL (ms) 
 
 
CV (m/s) 
 
 
Amp (mV) 
 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
 
37.7 
39.7 
32.7 
31.44 
32.44 
24.44 
77.1 
24.1 
28.1 
 
43.7 
47.7 
41.7 
84.44 
81.44 
81.44 
37.1 
31.1 
31.1 
 
11.7 
18.7 
78.7 
17.41 
32.41 
77.41 
17.1 
81.1 
77.1 
 
 
0.375 
 
 
0.694 
 
 
0.091 
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Discussion 
 
The results of this study clearly showed that 
the use of omega-3 or vitamin E-d supplements 
significantly reduced the incidence of peripheral 
neuropathy compared with placebo. However, there 
was no significant difference in the rate and severity of 
neuropathy in the two groups, and omega-3 and 
vitamin E did not have a significant superiority in this 
regard. Chemotherapy-induced peripheral neuropathy 
(CIPN) is a major clinical problem, which causes one 
of the dose-limiting side effects of some commonly 
used anti-neoplasms, such as taxol, cisplatin, and 
Vinca alkaloids. 
Table 4: Electrophysiological variables of sensory nerves 
during study period 
 Group Before 
chemotherapy 
One month 
later 
Three 
months 
later 
P-value 
Sural nerve 
DL (ms) 
 
 
CV (m/s) 
 
 
Amp (mV) 
 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
 
 
37.4 
21.4 
28.4 
24.41 
21.41 
77.41 
71.7 
79.7 
27.7 
 
94.3 
98.3 
74.4 
37.41 
34.41 
31.41 
38.7 
47.7 
12.7 
 
81.3 
87.3 
78.3 
29.47 
32.47 
47.47 
84.7 
87.7 
98.7 
 
 
1.121 
 
 
1.347 
 
 
1.447 
 
Ulnar nerve 
DL (ms) 
 
 
CV (m/s) 
 
 
Amp (mV) 
 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
Omega-3 
Vitamin E 
Placebo 
 
 
42.2 
47.2 
13.2 
71.11 
84.11 
13.11 
19.8 
71.8 
74.8 
 
 
13.2 
18.2 
73.2 
33.11 
47.11 
21.11 
77.8 
74.8 
12.8 
 
17.2 
83.2 
91.2 
81.49 
84.49 
37.49 
74.1 
14.1 
73.1 
 
 
1.311 
 
 
1.794 
 
 
1.197 
 
 
However, its onset may also affect the 
unpleasant quality of life in cancer patients, when 
CIPN is not a dose-limiting complication and causes 
chronic complications in these patients [12]. Studies 
show that 60-70% of patients receiving chemotherapy 
drugs are dose-dependent neurotoxicants [4]. Several 
studies have been conducted to reduce the incidence 
and severity of CIPN, but most of these studies have 
contradictory results. To best of our knowledge, no 
clinical study has compared the effects of omega-3 
fatty acids and vitamin E on the incidence of 
chemotherapy-induced neuropathy. 
On the other hand, until the completion of this 
study, only a few studies examined the effect of 
omega-3 on neuropathy. Meanwhile, Weymouth et al. 
only examined the role of omega-3 polyunsaturated 
fatty acids on diabetic neuropathy, which showed 
positive effects of omega-3 [13]. Another study 
specifically designed to evaluate the role of omega-3 
fatty acids in the prevention of taxol-induced 
peripheral neuropathy [11]. The results of the 
aforementioned clinical trial suggested that 30% of 
patients receiving Omega-3 and 59.3% of patients in 
the control group exhibited peripheral neuropathy. 
These findings are consistent with our study because 
only 28.6% of Omega-3-receiving patients had 
peripheral neuropathy in the present study. 
The findings of our study are consistent with 
previous studies that have examined the efficacy of 
fatty acids in diabetic neuropathy. These studies have 
shown that omega-3 fatty acids can reduce the 
severity of neuropathy in patients with type 2 diabetes 
[14] [15]. These micronutrients also reduced Na +/K + 
ATPase activity by reducing the neuronal conduction 
velocity in the sciatic nerve of the rats [16]. In a few 
pilot studies, vitamin E has been introduced as a 
neuroprotective agent [17] [18]. In a clinical study, 
patients undergoing paclitaxel-based chemotherapy 
received either chemotherapy with vitamin E [10]. The 
results of this Phase II clinical trial revealed that 
vitamin E, effectively and safely, could protect patients 
with cancer from paclitaxel-induced peripheral nerve 
damage. 
Kottschade et al. demonstrated that vitamin E 
did not change the incidence of neuropathy in these 
patients [19]. In a meta-analysis study published by 
Eum and colleagues, it has been shown that daily 
intake of 600-300 mg of vitamin E has significant 
effects on the reduction of neuropathy induced by 
chemotherapy [20]. On the other hand, there are 
studies that violate the positive effects of this vitamin 
in improving neuropathy. Huang et al., in a meta-
analysis study, believed that vitamin E could not 
reduce the incidence of CIPN [21]. They also said that 
a large sample size is needed to prove the 
effectiveness of this vitamin. 
In conclusion, taken together, our findings 
suggest that the use of food supplements such as 
vitamin E and omega-3s may significantly reduce the 
paclitaxel-induced neuropathy. The routine use of 
such supplements, which do not add to certain side 
effects for patients undergoing chemotherapy, can 
greatly increase their quality of life. 
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